Actively Recruiting
Open-label Study of mRNA-2808 for Adults With Relapsed or Refractory Multiple Myeloma Evaluating Safety and Tolerability
Led by ModernaTX, Inc. · Updated on 2026-09-23
190
Participants Needed
10
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and tolerability of mRNA-2808 in adults with relapsed or refractory multiple myeloma RRMM. This study focuses on patients who have previously received specific treatments including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies. The goal is to understand how participants respond to this investigational drug and monitor related side effects. Participants will receive mRNA-2808 administered either intravenously or subcutaneously. This is an open-label trial where all participants receive the study drug. The treatment period and dosing schedule are designed to evaluate dose-limiting toxicities and treatment-emergent adverse events over a 28-day and 15-month timeframe respectively. During the study, participants will undergo various assessments including monitoring for adverse events and measuring drug concentrations in the blood up to one year. Researchers will also evaluate disease response and survival outcomes over several years. Participants can expect regular visits for clinical evaluations, laboratory testing, and monitoring of their disease status throughout the studys duration, which extends up to six years for long-term outcomes.
CONDITIONS
Brief Title
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Research Team
M
Moderna WeCare Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here